Novo Nordisk takes amycretin for overweight into phase 3
Kort samengevat
Danish pharmaceutical company Novo Nordisk announces that both subcutaneous and oral amycretin are now moving into Phase 3 studies for the treatment of obesity. The decision is based on completed...
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij MarketScreener.
Lees het volledige bericht ↗